NCT04481204View on ClinicalTrials.gov

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

April 18, 2023

Primary Completion Date

April 6, 2027

Study Completion Date

April 6, 2027

Conditions
Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

Cisplatin

Given IV

DRUG

Fluorouracil

Given IV

DRUG

Gemcitabine

Given IV

DRUG

Irinotecan

Given IV

DRUG

Leucovorin

Given IV

DRUG

Nab-paclitaxel

Given IV

DRUG

Oxaliplatin

Given IV

RADIATION

Radiation Therapy

Undergo RT

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER